Iszema (Methylprednisolone Aceponate)

Iszema, a topical corticosteroid, is indicated for inflammatory dermatoses and related conditions.

• Eczema: reduces inflammation and relieves itching associated with the condition.
• Atopic dermatitis: controls flare‑ups and improves skin barrier function.
• Psoriasis: diminishes plaque formation and scaling.
• Contact dermatitis: alleviates redness and swelling caused by irritants or allergens.
• Other inflammatory skin disorders: provides anti‑inflammatory relief where conventional therapy is needed.

• Methylprednisolone aceponate penetrates the epidermis and binds to intracellular glucocorticoid receptors. The activated receptor complex translocates to the nucleus, where it modulates gene transcription, suppressing pro‑inflammatory cytokines, chemokines and adhesion molecules, thereby reducing inflammation and immune activation in the skin.

Topical application of Iszema may be associated with a range of local and systemic reactions.

Common Side Effects

• Burning or stinging sensation at the application site.
• Mild skin irritation or erythema.
• Dryness or peeling of the treated skin.
• Pruritus (itching) unrelated to the underlying disease.
• Folliculitis or acneiform eruptions.

Serious or Rare Side Effects

• Skin atrophy or thinning with prolonged use.
• Hypopigmentation or depigmentation of the skin.
• Allergic contact dermatitis to the formulation.
• Secondary bacterial, fungal or viral skin infections.
• Systemic effects such as hypothalamic‑pituitary‑adrenal axis suppression when large areas are treated.
• Delayed wound healing or ulceration.

When prescribing Iszema, clinicians should consider several safety measures.

• Assess severity: limit use to moderate‑to‑severe inflammatory skin conditions.
• Duration: avoid continuous use beyond recommended periods to prevent skin atrophy.
• Occlusion: do not apply under airtight dressings unless directed, as this increases systemic absorption.
• Concomitant steroids: avoid simultaneous use of other potent topical or systemic corticosteroids.
• Infections: monitor for signs of secondary bacterial, fungal, or viral infections.
• Store at room temperature: keep in the original container, protect from moisture and light.

Iszema may interact with other agents that affect corticosteroid activity or skin absorption.

Major Interactions (Avoid)

• Systemic corticosteroids: concurrent use can amplify systemic glucocorticoid effects.
• Potent CYP3A4 inhibitors applied to the same area: may increase local drug levels.
• Occlusive dressings: significantly enhance percutaneous absorption, raising risk of systemic side effects.

Moderate Interactions (Monitor Closely)

• Other topical immunosuppressants (e.g., tacrolimus): may increase risk of local skin irritation.
• Antifungal or antibacterial creams: assess for additive irritation or altered efficacy.
• Phototherapy: monitor for enhanced skin sensitivity when combined with topical steroids.